Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have divulged cytochrome P450 11B2, mitochondrial (CYP11B2; aldosterone synthase; ALDOS) inhibitors reported to be ...

Hansoh Pharmaceutical Group Co., Ltd. is a holding company, which engages in the research and development, production, and sale of a series of pharmaceutical products. Its products include ...

Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have divulged proprotein convertase subtilisin/kexin-type 9 (PCSK9) inhibitors acting as LDL-lowering agents ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Hansoh Pharmaceutical Group Company Limited (HK:3692) has released an update. Hansoh Pharmaceutical Group has announced the renewal of four innovative drugs in China’s 2024 National ...

GSK has turned to China’s Hansoh Pharma to add another antibody-drug conjugate (ADC) to its oncology pipeline, this time licensing a B7-H3-targeting candidate for $185 million upfront.

Merck & Co (MSD) has entered an exclusive global licence agreement with China-based Hansoh Pharma for a preclinical oral small molecule glucagon-like peptide 1 receptor agonist (GLP-1RA ...

Leverage fair value analysis to evaluate the market value of stocks enabling more informed investment decisions.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Merck (MRK) signed a licensing agreement with Chinese biotech company Hansoh Pharma (3692.HK) for its oral GLP-1 weigh-loss drug is valued as high as $2 billion. To watch more expert insights and ...